394 related articles for article (PubMed ID: 35924921)
1. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
[TBL] [Abstract][Full Text] [Related]
2. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
[TBL] [Abstract][Full Text] [Related]
3. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
[TBL] [Abstract][Full Text] [Related]
5. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
6. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
[TBL] [Abstract][Full Text] [Related]
7. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
[TBL] [Abstract][Full Text] [Related]
8. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
[TBL] [Abstract][Full Text] [Related]
9. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
13. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment.
Abdelnabi R; Jochmans D; Donckers K; Trüeb B; Ebert N; Weynand B; Thiel V; Neyts J
Nat Commun; 2023 Apr; 14(1):2124. PubMed ID: 37059708
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice.
Toomer G; Burns W; Garcia L; Henry G; Biancofiori A; George A; Duffy C; Chu J; Sides M; Muñoz M; Garcia K; Nikolai-Yogerst A; Peng X; Westfall L; Baker R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423193
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
[TBL] [Abstract][Full Text] [Related]
20. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters.
Roberts A; Vogel L; Guarner J; Hayes N; Murphy B; Zaki S; Subbarao K
J Virol; 2005 Jan; 79(1):503-11. PubMed ID: 15596843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]